Broad Clinical Labs published new research on communicating prostate cancer genetic risk to patients from the ProGRESS trial.
Public source
Publisher name
Public post
As genetic risk scores move into screening decisions, patient understanding matters as much as the science. New research on communicating prostate cancer genetic risk to…
Company
Broad Clinical Labs
Offering services to power your multi-omic data generation and analysis needs
- Industry
- Research Services
- Location
- Burlington, US
- Company size
- 51–200 employees
About Broad Clinical Labs
Broad Clinical Labs (BCL), a CLIA certified and CAP accredited wholly owned subsidiary (non-profit) of the Broad Institute, offers services to power your multi-omic data generation and analysis needs, across a range of research, translational, and clinical Dx applications.
See moreLatest activity
Latest activity from Broad Clinical Labs
4 signals
Research & Knowledge
Broad Clinical Labs and Broad Clinical Labs are part of the Somatic Mosaicism across Human Tissues (SMaHT) Network, which reports preprints of work by the NIH.
Products & Services
Broad Clinical Labs published a preprint from Nicolas Fernandez, Sami Farhi, and team at Broad Innovation Labs describing Celldega, a powerful toolkit for spatial transcriptomics data.
Research & Knowledge
Broad Clinical Labs published a preprint describing the creation of a 515,579-genome, multi-ancestry reference panel incorporating data from NIH's All of Us and NHGRI's AnVIL for genotype imputation.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Break Through Cancer
Break Through Cancer published a study in PNAS by the Eradicating Measurable Residual Disease in AML TeamLab team developing a personalized blood test that tracks up to 96 mutations specific to an individual patient’s leukemia.
Research & Knowledge
SOGUG - Spanish Oncology Genitourinary Group
SOGUG - Spanish Oncology Genitourinary Group published results from a clinical trial comparing olaparib plus abiraterona to placebo plus abiraterona in patients with mCRPC 1st line and mutations in a single gene, showing a 0.66 HR for overall survival in the global population with a 7.4 month improvement over placebo plus abiraterona.
Research & Knowledge
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology launched the ASPIRE trial (Alliance A032302) to answer whether adding chemotherapy to hormone therapy and apalutamide improves survival for men with metastatic prostate cancer.
Research & Knowledge
EORTC - European Organisation for Research and Treatment of Cancer
EORTC - European Organisation for Research and Treatment of Cancer published a new perspective from the EORTC Older Adult Council and the EORTC Quality of Life Group in the European Journal of Cancer highlighting the importance of integrating patient preferences into cancer clinical trials.
Research & Knowledge
Veracyte, Inc.